.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
The LiGHT randomized trial compared initial selective laser trabeculoplasty (SLT) with eye drops in treatment-naive patients with open-angle glaucoma or ocular hypertension. More than 700 participants were followed for three years, with an emphasis on disease control, quality of life, cost-effectiveness, and safety. The trial found similar health-related quality-of-life outcomes, while a large proportion of patients initially treated with SLT maintained target intraocular pressure without topical drops at 36 months. The laser-first pathway also avoided glaucoma surgery in the reported trial population and was highly cost-effective from the study's health-system perspective. The practical relevance is substantial: SLT can reduce dependence on daily topical therapy, avoid adherence problems, and provide a non-incisional treatment option early in the disease course. For glaucoma clinics, the decision still depends on angle anatomy, disease severity, access to laser, clinician expertise, and patient preference. The evidence supports presenting SLT as a legitimate first-line treatment rather than reserving it only for patients who fail drops. It also highlights the importance of discussing treatment burden alongside intraocular pressure when designing long-term glaucoma care.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
The LiGHT randomized trial compared initial selective laser trabeculoplasty (SLT) with eye drops in treatment-naive patients with open-angle glaucoma or ocular hypertension. More than 700 participants were followed for three years, with an emphasis on disease control, quality of life, cost-effectiveness, and safety. The trial found similar health-related quality-of-life outcomes, while a large proportion of patients initially treated with SLT maintained target intraocular pressure without topical drops at 36 months. The laser-first pathway also avoided glaucoma surgery in the reported trial population and was highly cost-effective from the study's health-system perspective. The practical relevance is substantial: SLT can reduce dependence on daily topical therapy, avoid adherence problems, and provide a non-incisional treatment option early in the disease course. For glaucoma clinics, the decision still depends on angle anatomy, disease severity, access to laser, clinician expertise, and patient preference. The evidence supports presenting SLT as a legitimate first-line treatment rather than reserving it only for patients who fail drops. It also highlights the importance of discussing treatment burden alongside intraocular pressure when designing long-term glaucoma care.
4 weeks back
A bioengineered oral nanozyme microsupplement converts pathological ROS into a protective polydopamine hydrogel shield. By curbing neutrophil extracellular traps and balancing T cells, this platform outperforms standard 5-ASA in preclinical colitis models, opening new paths for sustained remission.
2 days back
Recent research reveals that downregulating YAP1/TAZ-TEAD via Hippo signaling triggers spontaneous human trophoblast syncytialization in 3D cultures, illuminating placental biology and preeclampsia.
3 weeks back
Abdominal aortic aneurysm rupture remains a catastrophic vascular emergency. Groundbreaking research reveals that USP53 accelerates aneurysm progression by reprogramming smooth muscle cell metabolism toward aerobic glycolysis, highlighting a promising target beyond conventional diameter-based surveillance.
3 days back
A breakthrough study leverages natural language processing to accurately identify incident medication-related osteonecrosis of the jaw and track antiresorptive drug holidays from clinical narratives in electronic health records, advancing osteoporosis pharmacovigilance and dental safety.
3 days back
Recent research defines ferro-aging as a conserved iron-lipid axis driving organ decline across primates. Age-related iron dyshomeostasis stimulates ACSL4-mediated lipid peroxidation, promoting cellular senescence. Notably, vitamin C directly inhibits ACSL4, suppressing phospholipid oxidation and multi-organ decay.
3 days back
